Nanospectra Biosciences
L. Blair Shamel has Thirty years’ sales, marketing and commercialization experience in the business of prostate cancer. Launched first commercial assay for PSA. Experience includes Hybritech, Ablation Technologies, DiagnoCure, Metabolon and SNP Bio.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Nanospectra Biosciences
Nanospectra Biosciences develops particle-based therapies for the selective and precise thermal destruction of solid tumors.